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Abstract. Background/Aim: Multidrug resistance leads to
therapeutic difficulties. There is great interest in
experimental chemotherapy regarding multidrug resistance
inhibitors and new anticancer agents. The aim of this study
was to evaluate the anticancer activity of exocyclic sulfur
and selenoorganic compounds on mouse T-lymphoma cell
lines. Materials and Methods: A series of eighteen sulfur and
selenium analogues of 2[1H]-pyrimidinone and hydantoin
derivatives were evaluated towards their efflux modulating,
cytotoxic and antiproliferative effects in mouse T-lymphoma
cells. The combination assay with doxorubicin on multidrug
resistant mouse T-lymphoma cells was performed in order to
see the nature of drug interactions. Crystal structures were
determined for two selected compounds with the highest
efflux-modulating activity. Results: The sulfur analogues with
aromatic rings almost perpendicular to pyrimidinethione
ring at positions 1 and 6 showed the highest efflux inhibitory
action, while all selenium analogues showed good
antiproliferative and cytotoxic activities. Conclusion: The
sulfur analogues can be modified towards improving their
efflux inhibitory activity, whereas the selenium towards
antiproliferative and cytotoxic activities.
Cancer is still a major human health problem leading very
often to mortality. According to WHO data, cancer as the
second leading cause of death, was responsible for
approximately 14 million new cases in the year 2012 and
killed 8.8 million people in 2015 (1). There is still a need to
search for new anticancer drugs, due to the increasing
multidrug resistance leading to therapeutic difficulties. 
There is great interest in experimental chemotherapy
regarding multidrug resistance (MDR) inhibitors. The
cellular overproduction of MDR efflux pumps for example
ABCB1 (P-glycoprotein, P-gp) is one of the more relevant
mechanisms underlying MDR, which is capable to promote
the efflux of cytotoxic drugs out of the cells (2). ABCB1
belongs to the ATP-binding cassette (ABC) transporter
proteins, involved in the transport of various substrates e.g.
cholesterol, drugs, chloride ion, toxins, across membranes
(3). In cancer cells, the overexpression of ABCB1 is
responsible for reduction of the intracellular concentration of
the anticancer drugs, which in consequence leads to
treatment failure (4). It should be pointed out that several
clinical trials targeting ABCB1 with small molecules, first-
generation (verapamil, cyclosporine A, quinidine) (5, 6),
second-generation (dexverapamil, cinchonine, valspodar) (7,
8) and third-generation (zosuquidar, tariquidar, laniquidar)
inhibitors have failed due to their toxicity (9, 10). Finding
non-toxic inhibitors, capable of decreasing the ABCB1-
mediated drug efflux, is a promising strategy for improving
the effectiveness of cancer treatment.
Recently, a number of different compounds were designed
as potential MDR modulators, including new chemical
groups of ABCB1 inhibitors, i.e. derivatives of xanthone
(11), benzoxanthone (12), hydantoin and thiohydantoin (13,
14), benzodipyranone (15), indol alkaloid (16), selenoesters
(17, 18), epigallocatechin and dihydromyricetin (19).  
Taking this into consideration, we decided to evaluate
eighteen sulfur and selenium analogues of 2[1H]-pyrimidinone
(1-8) and hydantoin (9) derivatives (Figure 1) towards their
efflux modulating, cytotoxic and antiproliferative effects in
sensitive and resistant mouse T-lymphoma cells. Furthermore,
the selected compounds were investigated in combination with
the anticancer drug doxorubicin. The aim of our study was to
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compare the biological activity of sulfur and selenium
compounds and to analyze crystal and molecular structures in
the search of a structural feature that can be responsible for
their activity.
The investigated compounds were synthesized according to
the procedures published earlier (20, 21). In this paper, two
new crystal structures of selected 2[1H]-pyrimidinethione
derivatives are reported: 4-methyl-1-(4-methylphenyl)-6-
phenyl-2[1H]-pyrimidinethione (3S) and 4-methyl-1-(4-
methoxyphenyl)-6-phenyl-2[1H]-pyrimidinethione (4S). These
compounds differ in the substituent at the aromatic ring and
show the best activity towards inhibition of ABCB1, wherein
the activity of 4S is 3-fold higher than that of 3S. The
arrangement of rings may be related to the biological activity.
In order to see mutual orientation of all three rings, a deeper
insight into the structural properties of the presented
compounds was performed with the use of X-ray diffraction
analysis. Moreover, we compared crystal structures of active
compounds with the known crystal structure of the not active
compound 1S (22). We present the results of the biological
studies of sulfur (1S-9S) and selenium (1Se-9Se) analogues of
pyrimidinone and hydantoin derivatives (Figure 1) in order to
see how the change of the sulfur atom to selenium can
influence the ABCB1 inhibition, cytotoxic and antiproliferative
activities. 
Materials and Methods 
Crystal structures determination. Crystals suitable for X-ray
structure analysis were obtained from ethanol solution by slow
evaporation of the solvent at room temperature. The intensity data
were collected on the Bruker-Nonius Kappa CCD four circle
diffractometer equipped with a Mo (0.71069 Å) Kα radiation source.
The phase problem was solved by direct methods using SHELXS
and the structures were refined by SHELXL (23) programs. For
molecular graphics MERCURY (24) program was used.
Compound 3S: C18H16N2S, Mr=292.39, crystal size=0.04×0.18×
0.41 mm3, monoclinic, space group P21/c, a=10.9600(2) Å,
b=25.4850(5) Å, c=12.9280(2) Å, β=121.028(1)°, V=3094.3(1) Å3,
Z=8, T=100(2) K, 22,417 reflections collected, 7,059 unique
reflections [Rint=0.0474], R1=0.0429, wR2=0.0870 [I>2sigma(I)].
Compound 4S: C18H16N2OS, Mr=308.39, crystal size=0.17×0.36×
0.55 mm3, monoclinic, space group P21/c, a=12.6920(3) Å,
b=8.9240(2) Å, c=16.8230(3) Å, β=125.283(2)°, V=1555.42(7) Å3,
Z=4, T=100(2) K, 12217 reflections collected, 3556 unique
reflections [Rint=0.0334], R1=0.0346, wR2=0.0849 [I>2sigma(I)].
CCDC 1833588 and 1833589 contain the supplementary
crystallographic data for 3S and 4S, respectively. These data can be
obtained free of charge from The Cambridge Crystallographic Data
Centre via www.ccdc.cam.ac.uk/data_request/cif. 
Biological assays
Cell lines. The L5178Y mouse T-lymphoma cells (PAR) (ECACC
Cat. No. 87111908, obtained from FDA, Silver Spring, MD, USA)
were transfected with pHa MDR1/A retrovirus (25). The ABCB1-
expressing cell line L5178Y (MDR) was selected by culturing the
infected cells with colchicine. L5178Y (parent) mouse T-cell
lymphoma cells and the L5178Y human ABCB1 transfected subline
were cultured in McCoy’s 5A medium (Sigma-Aldrich, Steinheim,
Germany) supplemented with 10% heat-inactivated horse serum
(Sigma-Aldrich), 200 mM L-glutamine (Sigma-Aldrich) and a
penicillin streptomycin (Sigma-Aldrich) mixture in concentrations
of 100 U/l and 10 mg/l, respectively. 
Rhodamine-123 (R123) accumulation assay by flow cytometry. The
cell number of L5178Y MDR and L5178Y parental cell lines were
adjusted to 2×106 cells/ml, re-suspended in serum-free McCoy’s
5A medium and distributed in 0.5 ml aliquots into Eppendorf
centrifuge tubes. The tested compounds were added at 2 and 20 μM
concentrations and the samples were incubated for 10 min at room
temperature. Verapamil (purity: ≥99%; Sigma-Aldrich) was applied
as positive control. DMSO at 2% was also added as solvent
control. Next, 10 μl (5.2 μM final concentration) of the
fluorochrome and ABCB1 substrate R123 (Sigma-Aldrich) were
added to the samples and the cells were incubated for further 20
min at 37˚C, washed twice and re-suspended in 0.5 ml PBS for
analysis. The results obtained from a representative flow cytometry
experiment measuring 20,000 individual cells of the population
were evaluated using Partec CyFlow® flow cytometer (Partec,
Münster, Germany). The percentage of mean fluorescence intensity
was calculated for the treated MDR cells as compared with the
untreated cells. A fluorescence activity ratio (FAR) was calculated
based on the following equation which relates to the measured
fluorescence values:
Assay for cytotoxic and antiproliferative effect. The compounds
were diluted in a volume of 100 μl medium. Then, 1×104 cells (for
cytotoxic assay) and 6×103 (for antiproliferative assay) in 100 μl of
medium were added to each well, with the exception of the medium
control wells (17). The culture plates were incubated at 37˚C for 24
and 72 h; at the end of the incubation period, 20 μl of MTT
(thiazolyl blue tetrazolium bromide; Sigma-Aldrich) solution (from
a 5 mg/ml stock) were added to each well. After incubation at 37˚C
for 4 h, 100 μl of SDS (sodium dodecyl sulfate; Sigma-Aldrich)
solution (10% in 0.01 M HCI) were added to each well and the
plates were further incubated at 37˚C overnight. Cell growth was
determined by measuring the optical density (OD) at 540 nm (ref.
630 nm) with Multiscan EX ELISA reader (Thermo Labsystems,
Cheshire, WA, USA). Inhibition of the cell growth was determined
according to the formula:
Checkerboard combination assay. The dilutions of doxorubicin (2
mg/ml, Teva Pharmaceuticals, Budapest, Hungary) were made in a
horizontal direction in 100 μl, and the dilutions of the resistance
modifiers vertically in the microtiter plate in 50 μl volume. The
L5178Y MDR mouse T-lymphoma cells were re-suspended in
culture medium and distributed into each well in 50 μl containing
6×103 cells, with the exception of the medium control wells, to a
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final volume of 200 μl per well. The plates were incubated for 72 h
at 37˚C in a CO2 incubator and at the end of the incubation period,
the cell growth was determined by the MTT staining method, as
earlier described. Drug interactions were evaluated using CompuSyn
software. Combination index (CI) values at 50% of the growth
inhibition dose (ED50), were determined using CompuSyn software
(www.combosyn.com, ComboSyn, Inc., Paramus, NJ, USA) to plot
four to five data points to each ratio. CI values were calculated by
means of the median-effect equation, where CI<1, CI=1, and CI>1
represent synergism, additive effect (or no interaction), and
antagonism, respectively.
Results
Crystal and molecular structures. The projections of
molecular geometry in the crystal structures with the atom
numbering are shown in Figure 2. The asymmetric unit of
3S consists of two independent molecules (one molecule is
labeled as A, the second as B), while 4S one molecule.
The angle between the plane of 2[1H]-pyrimidinethione
ring and the plane of aromatic ring at N1 atom is 67.02(6)°,
78.27(6)° and 82.82(5)°, whereas between the plane of
2[1H]-pyrimidinethione ring and aromatic ring at C6 is
56.14(7)°, 64.24(6)° and 76.16(5)° for 3S molecule A, 3S
molecule B and 4S, respectively. The angle between the
planes of two aromatic rings is 59.95(6)°, 66.27(6)° and
62.27(5)° for 3S molecule A, 3S molecule B and 4S,
respectively. 
The selected torsion angles, observed in the crystal
structures of 1,6-diphenyl-2[1H]-pyrimidinethione derivatives
presented in this paper and determined earlier (22), are listed
in Table I. The comparison of them shows the slight
differences of mutual orientations of aromatic rings and
2[1H]-pyrimidinethione ring. 
Nitrogen and sulfur atoms as acceptors and hydrogen
atoms directly bonded to carbon atoms as donors, are
engaged in weak intermolecular hydrogen bonds. Parameters
of these interactions are listed in Table II. In the crystal
structure of 3S carbon atoms of all three rings are engaged
in intermolecular contacts, whereas in 4S only carbon atoms
of aromatic rings and the methyl group at C4 atom.
Substituents at aromatic ring are not engaged in any
intermolecular interactions. There is an oxygen atom in the
structure of 4S, which could be an acceptor in hydrogen
bonds, but in the presented crystal structure is not involved
in any intermolecular hydrogen bonds. 
Efflux modulating effects. The efflux-modulating effects of
1S-9S and 1Se-9Se were investigated in the sensitive
parental (PAR) and resistant (MDR) mouse T-lymphoma
cells overexpressing ABCB1 using the standard R123
functional assay (17). The results are expressed as the
fluorescence activity ratio (FAR) values, which represent the
accumulation of R123 in L5178Y-MDR and L-5178Y-PAR
cells (Figure 3). When FAR value is higher than one, the
modulation of ABCB1 occurs, while FAR value that is
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Figure 1. Chemical structures of investigated compounds.
Table I. The comparison of selected torsion angles [°] for 1,6-diphenyl-
2[1H]-pyrimidinethione derivatives.
Torsion angle                  1S              3S (A)            3S (B)              4S
C2-N1-C7-C8           –81.0(1)        –70.9(2)          –80.7(2)       –85.6(2)
C2-N1-C7-C12         100.7(1)        110.3(2)            98.2(2)         97.4(2)
N1-C6-C13-C14       –68.9(2)        –56.6(2)          –65.9(2)       –77.1(2)
N1-C6-C13-C18        111.9(1)        129.6(2)          119.8(2)       108.2(2)
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Figure 2. The molecular structures of 3S (molecule A) and 4S in the crystalline state.
higher than ten implicates strong modulation (26). The
modulating effect was observed for almost all 1,6-diphenyl-
2[1H]-pyrimidinethione/selenone derivatives (1-4), but only
five compounds were more effective than the reference
inhibitor verapamil and two of them (3S and 4S) showed
strong modulation of ABCB1 at 20 μM. Other 1,4-diphenyl-
2[1H]-pyrimidinethione/selenone derivatives (5-8) and
thiohydantoin/selenohydantoin derivative (9) displayed lower
activity than verapamil at 20 μM. The tested compounds had
no efflux pump inhibiting effect at 2 μM. 
Cytotoxic and antiproliferative effects. All compounds were
examined for their cytotoxic effect in sensitive (PAR) and
resistant (MDR) mouse T-lymphoma cells (17). As shown in
Table III, all selenium analogues displayed cytotoxicity in
both cell lines. Almost all sulfur analogues with the
exception of two (5S and 9S) showed no cytotoxic effect
(IC50 >100 μM) in the mouse T-lymphoma cell lines. 
The antiproliferative activity of the presented compounds
was investigated in sensitive (PAR) and resistant (MDR)
mouse T-lymphoma cells (Table III) (27). The tested
selenium analogues (1Se-9Se) showed significant
antiproliferative profiles with IC50 in the range 0.9-1.7 μM
for 1Se-4Se, 2.0-4.5 μM for 5Se-9Se. The sulfur analogues
displayed much weaker activity from 35 to over 100 μM
except for 5S and 9S.
Checkerboard combination assay. For compounds with
efficient antiproliferative activity (1Se-9Se, 5S and 9S), their
ability to make MDR cells more susceptible to anticancer
drug action was assessed using checkerboard combination
assay. These compounds were tested together with the
anticancer drug doxorubicin in order to get information about
the nature of interactions between them (Table IV). In Table
IV the best combination ratios of doxorubicin and tested
compounds are presented. Combination index (CI) in the
third column (Table IV) is based on the 50% of the growth
inhibition dose (ED50). The nature of interactions is
determined on the basis of the CI value as a synergism
(CI<1), antagonism (CI>1) or additive effect (CI=1) (28).
Discussion
Previously, several classes of compounds have been
described as cytotoxic agents, adjuvants in combination with
doxorubicin, ABCB1 modulators and apoptosis inducers,
such as phenothiazines (29), steroidal compounds (30) and
hydantoin derivatives (31). The presented compounds
showed different biological activities. The analyzed
compounds contain two aromatic rings in three different
locations: (i) 1-4 possess the closest phenyl substituents, in
N1 and C6 positions of 2[1H]-pyrimidinethione/selenone
ring; (ii) 5-8 have the most distant phenyl substituents, in N1
and C4 positions of 2[1H]-pyrimidinethione/selenone ring
and (iii) 9 contains the distant phenyl substituent at N3 and
benzylidene substituent at C5 of 2-thio/selenohydantoin ring
(Figure 1). The positions of the aromatic rings and the
presence of sulfur or selenium atom are connected with
biological activities. 
The results obtained for the modulation of ABCB1
mediated efflux showed the best activity for sulfur analogues
with phenyl substituent at neighboring atoms (N1 and C6)
defined as location (i). These compounds showed also no
cytotoxic effects in both cell lines (PAR and MDR). A deeper
insight into the structural properties of the 1,6-
diphenylpyrimidinethione derivatives (1S, 3S, 4S) using the
X-ray crystal structure analysis allowed us to determine the
mutual orientation of the rings. Compound 4S with highest
activity towards inhibition of ABCB1 showed the
conformation with aromatic rings the closest to perpendicular
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Table II. Parameters of weak intermolecular hydrogen bonds.
Comp.                           D-H•••A                                H•••A [Å]                      D•••A [Å]                     D-H•••A [°]                                 Symmetry codes
3S                           C5A-H3A•••N3B                             2.45                           3.383(2)                            166                                        x, -y+1/2, z+1/2
                               C5B-H3B•••N3A                             2.74                           3.558(2)                            148                                       x-1, -y+1/2, z-1/2
                               C5B-H3B•••S1A                             2.78                           3.629(2)                            150                                       x-1, -y+1/2, z-1/2
                               C8B-H8B•••N3B                             2.65                           3.353(2)                            131                                              -x, -y, -z
                               C8B-H8B•••S1B                             2.82                           3.757(2)                            170                                              -x, -y, -z
                            C11A-H11A•••N3A                           2.74                           3.331(2)                            121                                        x, -y+1/2, z+1/2
                             C12A-H12A•••S1A                           3.08                           3.969(2)                            157                                        x, -y+1/2, z+1/2
                             C16B-H16B•••S1B                           3.02                           3.720(2)                            132                                               x-1, y, z
                             C17B-H17B•••S1A                           2.83                           3.708(2)                            154                                               x-1, y, z
4S                               C9-H9•••N3                                 2.76                           3.471(2)                            134                                          -x+1, -y, -z+1
                                 C12-H12•••N3                               2.52                           3.363(2)                            152                                        -x+1, -y+1, -z+1
                                 C16-H16•••N3                               2.74                           3.637(2)                            163                                      x+1, -y+1/2, z+1/2
                                C19-H19A•••S1                              3.03                           3.948(2)                            160                                        x, -y+1/2, z+1/2
to the plane of 2[1H]-pyrimidinethione ring. Other
compounds possessed these rings more twisted. Compound
1S, containing unsubstituted aromatic rings, was not more
active than verapamil, while introducing the substituent to
aromatic ring at N1 atom increased this activity. The
introduction of an electron-withdrawing substituent, namely
chlorine atom (2S), led to a 7-fold increase in the efflux
modulatory effect. However, an electron-donating substituent
in aromatic ring, namely methyl group (3S), increased 11-
fold the efflux modulatory effect, while methoxy group (4S),
a stronger electron-donating substituent increased 30-fold
ABCB1 inhibiting activity. 
Interestingly, the replacement of sulfur atom with
selenium atom increased almost 8-fold the activity of 1Se in
comparison to 1S. The comparison of molecular geometries
of these two compounds did not show significant differences
(22). In this case the presence of selenium atom seems to be
important for biological activity. However, the chlorine
substituent in aromatic ring decreased the capacity of 2Se to
inhibit the ABCB1 efflux pump, giving a value of FAR
almost the same as for 1S. The introduction of a methyl
substituent to the aromatic ring in 1Se (compound 3Se)
improved activity in comparison to 2Se, while the presence
of methoxy group in 4Se caused a lower activity than
verapamil.
Cytotoxic activity among investigated compounds is
mainly related to the presence of the selenium atom. The role
of the aromatic rings’ locations seems to be less important.
All selenium analogues displayed high cytotoxic effects in
both sensitive and resistant cell lines. Only two sulfur
analogues (5S and 9S) showed cytotoxic activity. Sulfur
analogues with modulating effect on ABCB1 (1S-4S) were
not cytotoxic on the tested lines. 
The capacity of the investigated compounds regarding
antiproliferative activity is correlated with the cytotoxicity
effect: all cytotoxic selenium analogues displayed
antiproliferative activity with IC50 in the range of 0.9-6 μM
in both cell lines (PAR and MDR). The sulfur analogues,
excluding 5S and 9S, showed 10-fold weaker antiproliferative
activity. The combination assay with doxorubicin on MDR
cells for compounds with potent antiproliferative activity
showed that selenium derivatives with (i) location of the rings
(1Se-4Se) displayed antagonism, derivatives with (ii) location
(5Se-8Se) moderate antagonism/synergism, while the third
group (iii), namely derivative of 2-thio/selenohydantoin (9S,
9Se), synergism. 
To summarize, the presented results allowed us to identify
new compounds (1S-4S) showing potency to inhibit the
cancer MDR efflux pump ABCB1. The introduction of an
electron-donating substituent in the phenyl ring at N1 atom
increased the activity. These results point out the 1,6-
diphenyl-2[1H]-pyrimidinethione scaffold for further
structural modifications in order to improve the efflux
modulation on ABCB1. For the most active compound (4S)
the mutual orientations of aromatic and pyrimidinethione
rings show the closest angles to 90 degrees between the
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Figure 3. Rhodamine 123 retention in the presence of the compounds at 20 μM and verapamil at 20 μM as a positive control on multidrug-resistant
T-lymphoma cells (MDR).
rings. All selenium analogues showed very potent cytotoxic
and antiproliferative activities. Two derivates of the 1,4-
diphenyl-2[1H]-pyrimidineselenone (5Se, 7Se) exerted a
synergistic effect in combination with doxorubicin. Both 2-
thiohydantoin and 2-selenohydantoin derivatives (9S, 9Se)
improved the cytotoxicity of doxorubicin synergistically.
Acknowledgements
The Authors would like to thank Prof. Jadwiga Handzlik for her
comprehensive discussion. The work was supported by Pedagogical
University of Cracow (BS-465/G/2018).
References 
1 WHO Media Centre, Fact sheet N°297, February 2017.
http://www.who.int/mediacentre/factsheets/fs297/en/. 
2 Linton KJ and Higgins CF: Structure and function of ABC
transporters: the ATP switch provides flexible control. Pflugers
Arch 453: 555-567, 2007. 
3 Hegedüs C, Truta-Feles K, Antalffy G, Várady G, Német K,
Ozvegy-Laczka C, Kéri G, Orfi L, Szakács G, Settleman J,
Váradi A and Sarkadi B: Interaction of the EGFR inhibitors
gefitinib, vandetanib, pelitinib and neratinib with the ABCG2
multidrug transporter: Implications for the Emergence and
reversal of cancer drug resistance. Biochem Pharmacol 84: 260-
267, 2012.
4 Gottesman MM, Fojo T and Bates SE: Multidrug resistance in
canser: role of ATP-dependent transporters. Nat Rev Cancer 2:
45-48, 2002.
5 Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y: Overcoming of
vincristine resistance in P388 leukemia in vivo and in vitro
through enhanced cytotoxicity of vincristine and vinblastine by
verapamil. Cancer Res 41: 1967-1972, 1981.
6 Foxwell BM, Mackie A, Ling V and Ryffel B: Identification of
the multidrug resistance-related P-glycoprotein as a cyclosporine
binding protein. Mol Pharmacol 36: 543-546, 1989.
7 Mickisch GH, Noordzij MA, Gaast A, Gebreamlack P,
Köhrmann KU, Mogler-Drautz E, Kupper H and Schröder FH:
Dexverapamil to modulate vinblastine resistance in metastatic
renal cell carcinoma. J Cancer Res Clin Oncol 121(Suppl 3):
R11-R16, 1995.
8 Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A,
Bollinger P and Loor F: In vivo circumvention of P-
glycoprotein-mediated multidrug resistance of tumor cells with
SDZ PSC 833. Cancer Res 51: 4226-4233, 1991.
9 Palmeira A, Sousa E, Vasconcelos MH and Pinto MM: Three
decades of P-gp inhibitors: skimming through several generations
and scaffolds. Curr Med Chem 19(13): 1946-2025, 2012.
10 Nobili S, Landini I, Giglioni B and Mini E: Pharmacological
strategies for overcoming multidrug resistance. Curr Drugs
Targets 7: 861-879, 2006.
11 Chae SW, Woo S, Park JH, Kwon Y, Na Y and Lee HJ:
Xanthone analogues as potent modulators of intestinal P-
glycoprotein. Eur J Med Chem 93: 237-245, 2015.
12 Chae SW, Lee J, Park JH, Kwon Y, Na Y and Lee HJ: Intestinal
P-glycoprotein inhibitors, benzoxanthone analogues. J Pharm
Pharmacol 70: 234-241, 2018.
Żesławska et al: Sulfur and Selenoorganic Compounds as Anticancer Agents
4583
Table III. Cytotoxic and antiproliferative effects of the compounds on
sensitive L5178Y parental (PAR) and resistant (MDR) mouse T-lymphoma
cells.
Compound                                              IC50 [μM]
                                    Cytotoxic effect               Antiproliferative effect
                                 PAR                 MDR               PAR              MDR
1S                             >100                 >100             53±1.99        54.3±0.85
1Se                       1.04±0.09         1.29±0.02        1.4±0.26        1.5±0.12
2S                            >100                 >100             47±1.99         36±2.22
2Se                       0.77±0.77         1.08±0.03         0.9±0.1        1.14±0.05
3S                            >100                 >100             47±0.58         64±1.99
3Se                       0.77±0.09         1.06±0.05       1.17±0.03       1.7±0.09
4S                            >100                 >100             50±1.36         56±2.64
4Se                       0.79±0.01         1.09±0.01       1.15±0.03      1.58±0.04
5S                           8.17±0             15±1.04          8.6±0.24       12.9±0.15
5Se                       1.26±0.04         1.48±0.08        2.2±0.14       2.61±0.08
6S                            >100                 >100             35±5.43         54±2.96
6Se                        3.1±0.22           4.1±0.12         3.4±0.27        4.1±0.16
7S                            >100                 >100             82±2.88            >100
7Se                       2.03±0.09          2.9±0.07          2.±0.19        2.13±0.05
8S                            >100                 >100               85±4              >100
8Se                         4.39±0            4.4±0.26         3.6±0.22       4.51±0.07
9S                         14.5±0.34          14±2.48          4.5±0.16          8±1.45
9Se                        5.5±0.49            9±2.81            6±0.37           4±0.73
Doxorubicin         0.7±0.56          2.14±0.76       0.28±0.06      1.75±0.38
Table IV. Type of interaction between compounds and doxorubicin
against multidrug-resistant (MDR) mouse T-lymphoma cells.
Compound       Best ratioa       CI at ED50b                   Interaction
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